(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases...
Stats | |
---|---|
Today's Volume | 148 854 |
Average Volume | 399 921 |
Market Cap | 89.09M |
EPS | £0 ( 2024-01-30 ) |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -9.60 |
ATR14 | £0.0850 (0.90%) |
Scancell Holdings PLC Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Scancell Holdings PLC Financials
Annual | 2022 |
Revenue: | £5.27M |
Gross Profit: | £4.75M (90.04 %) |
EPS: | £-0.0146 |
FY | 2022 |
Revenue: | £5.27M |
Gross Profit: | £4.75M (90.04 %) |
EPS: | £-0.0146 |
FY | 2022 |
Revenue: | £0 |
Gross Profit: | £0 (0.00 %) |
EPS: | £-0.00250 |
FY | 2021 |
Revenue: | £0.00 |
Gross Profit: | £0.00 (0.00 %) |
EPS: | £-0.0392 |
Financial Reports:
No articles found.
Scancell Holdings PLC
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators